Endometrioid adenocarcinoma presenting in a patient 18 years after hysterectomy: a potential hazard of unopposed oestrogen therapy
- Alvaro Bedoya Ronga1,
- Salim K Najia2,
- Neil Sahasrabudhe3,
- Richard Prescott3,
- Felicia Elena Buruiana4,
- Alexander Heazell2
- 1Stoke Mandeville Hospital, Obstetrics and Gynaecology, Flat C, 17-19 Guildford Street, Luton LU1 2NQ, UK
- 2Royal Blackburn Hospital, Obstetrics & Gynaecology, Haslingden Road, Blackburn BB2 3HH, UK
- 3Royal Blackburn Hospital, Pathology, Haslingden Road, Blackburn BB2 3HH, UK
- 4Leicester Royal Infirmary, Dermatology, Infirmary Square, Leicester LE1 5WW, UK
- Alvaro Bedoya Ronga, abedoyaronga{at}yahoo.co.uk
- Published 13 August 2009
Summary
We present a case of endometrioid adenocarcinoma arising from extragonadal endometriosis 18 years after total abdominal hysterectomy with bilateral salpingo-oophorectomy. After the primary surgery the patient received 11 years of unopposed oestrogen hormone replacement therapy. She presented with symptoms of urinary retention and pelvic mass. Following resection, histopathology identified the mass as an endometrioid adenocarcinoma. The association between persistent endometriosis and the development of endometrial cancer are discussed here together with the risks of unopposed oestrogen in the development of such lesions.
Footnotes
-
Competing interests: none.
-
Patient consent: Patient/guardian consent was obtained for publication








